News

Kiora also stated a Phase 2 trial of KIO-104 is expected to begin later this year

The study showed that a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye.

Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Investigators emphasised that the data does not indicate a causal relationship between the eye disorder and systemic diseases

The retina specialist shares advice for the clinician-scientists of a digital-centric future

TL-925 is a first in class, topical Bruton’s tyrosine kinase (BTK) inhibitor that prevents mast cell activation and degranulation, and also blocks the cytokine-driven inflammatory response, and restores lacrimal unit homeostasis, offering the potential for disease modification

Jeff Todd, president and CEO of Prevent Blindness, and astrophotographer Jon Carmichael sat down with David Hutton of Ophthalmology Times to talk about how ophthalmologists can help make sure patients are viewing the eclipse safely as well as proper ways to view/photograph the event without damaging your eyes or equipment.

Study concluded that the short-term results of LBN to treat mild-to-modern OAG and OHT was safe and efficacious.

Filomena Ribeiro, MD, PhD, FEBO, discusses the crucial role of mentors – and where to find them

The company has divested its Coherus Ophthalmology subsidiary to Sandoz, Inc. for upfront all-cash consideration of $170 million.

Early detection of the disease is key to optimal patient outcomes

Eyenovia acquired the US commercial rights for the drug last August from Formosa Pharmaceuticals.

Investigators believe that AMD and cancer may have similar risk factors in common.

Day 2 program of the 2024 COPHy conference.

Clara Chan, MD, shares surgical pearls for neurotrophic keratopathy and explores new pathways through neurotisation

The approval marks the first new steroid on the US ophthalmic market in more than 15 years

The approval marks the first new steroid on the ophthalmic market in more than 15 years.

The 2024 15th annual Controversies in Ophthalmology Congress will convene March 15 and 16 in Athens, Greece.

ChatGPT-4 (OpenAI) had an overall “fair” performance when answering multiple-choice ophthalmic questions unrelated to multifocal imaging.

Andrew G. Iwach, MD, recounts two personal life experiences that underscore the significance of patient-centered care in glaucoma management.

Early detection of the disease is key to optimal patient outcomes

A longitudinal, AI-based approach to fluid quantification

After completing his residency at the Wilmer Eye Institute and a fellowship at NIH, Walter J. Stark, MD, returned to Wilmer for a 40-year career as a surgeon, teacher, researcher, and Boone Pickens Professor of Ophthalmology and chief of the Cornea Division.

During the 2024 American Glaucoma Society meeting held February 29 to March 3 in Huntington Beach, California, Nixoc SA presented posters outlining data on NCX 470.

Mobile cameras allow University of Colorado ophthalmology residents working in hospital settings to conduct more comprehensive and efficient patient evaluations.